Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer

Gynecologic Oncology

Volumn 83, Issue 1, 2001, Pages 128-134

  Gronlund, Bo ^a   Hogdall, Claus ^a   Hansen, Heine H ^a   Engelholm, Svend A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Carboplatin; Chemotherapy; Epithelial ovarian cancer; Overall survival; Paclitaxel; Prognostic factors; Progression free interval; Progression free survival; Relapsed or recurrent disease; Response; Second line treatment

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MULTIVARIATE ANALYSIS; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034799395     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6364     Document Type: Article

References (25)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
2. Advanced epithelial ovarian cancer: 1998 Consensus statements
3. Chemotherapy of advanced ovarian cancer
4. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
5. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial
6. Randomised phase III study of cisplatin-paclitaxel versus carboplatin-paclitaxel in optimal stage III epithelial ovarian cancer: A Gynecologic Oncology Group Trial (GOG 158)
7. Treatment of recurrent ovarian cancer: Increasing options - "Recurrent" results
8. Advances in ovarian cancer chemotherapy
9. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma
10. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens
11. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study
12. Appendix I: Definitions of response
13. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
14. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials
15. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population
16. "Recurrence within 6 months of platinum therapy": An adequate definition of "platinum-refractory" ovarian cancer?
17. Current status of chemotherapy in gynecologic cancer
18. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer
19. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group D'Investigateurs Nationaux Pour L'Etude Des Cancers Ovariens) phase II study
20. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience
21. Salvage weekly paclitaxel in recurrent ovarian cancer
22. Paclitaxel vs CAP in recurrent platinum sensitive ovarian cancer: A randomized phase II study
23. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
24. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: A prediction tree analysis-derived model with test and validation groups
25. Ovarian cancer: Should we be managing patients with good and bad prognostic factors in the same manner?